Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports

Group 1 - Pfizer is nearing a potential acquisition of Metsera, a developer of anti-obesity drugs, valued at $7.3 billion [1] - The information regarding the acquisition was reported by the Financial Times, citing unidentified sources [1] Group 2 - The acquisition reflects Pfizer's strategic interest in expanding its portfolio in the anti-obesity drug market [1] - Metsera's development focus aligns with the growing demand for obesity treatments, indicating a significant market opportunity [1]